FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012533421> ?p ?o ?g. }

• W2012533421 endingPage "40" @default.
• W2012533421 startingPage "33" @default.
• W2012533421 abstract "ObjectiveAneurysm growth after endovascular aneurysm repair (EVAR) in patients with type II endoleak is associated with adverse outcomes. This study evaluated the long-term success of embolization of type II endoleaks in preventing aneurysm sac growth.MethodsWe retrospectively reviewed outcomes of patients who underwent infrarenal EVAR who were treated for a type II endoleak between 2000 and 2008. Computed tomography scans were evaluated for aneurysm sac growth or shrinkage from the time of treatment of the endoleak. The embolization material used, graft type, target vessel embolized, and comorbidities were evaluated for their association with sac growth or shrinkage.ResultsNinety-five patients underwent 140 embolization procedures. The mean time from EVAR to embolization was 26.1 ± 22.2 months, and the average increase in size of the aneurysm sac from EVAR to treatment was 0.7 × 0.5 cm. Patients underwent an average of 1.6 ± 0.8 embolization procedures after EVAR. Thirteen patients underwent initial simultaneous embolization of two targets. Embolization was with glue (61%), coils (29%), glue and coils (7%), and Gelfoam (3%; Pfizer Inc, New York, NY). No abdominal aortic aneurysms (AAA) ruptured. Eight patients (8.4%) underwent graft explant and open repair; 19 (20%) required two or more embolization procedures. There was no difference in the target vessel treated or the treatment used in halting sac expansion (>5 mm). Coil embolization alone resulted in more second procedures. The 5-year cumulative survival was 65% (95% confidence interval [CI], 52%-77%), freedom from explant was 89% (95% CI, 81%-97%), freedom from second embolization was 76% (95% CI, 66%-86%), and freedom from sac expansion >5 mm was 44% (95% CI 30%-50%). Univariable analysis identified continued tobacco use (hazard ratio [HR], 2.30; 95% CI, 1.02-5.13; P = .04) was associated with continued sac expansion, and hyperlipidemia (HR, 9.64; 95% CI, 2.22-41.86) was associated with patients requiring a second embolization procedure.ConclusionsEmbolization of type II endoleaks is successful early in preventing aneurysm sac growth and rupture after EVAR. However, a significant number of patients require more than one procedure, and at 5 years, many patients who underwent embolization of a type II endoleak continued to experience sac growth. Patients with hyperlipidemia who undergo coil embolization are more likely to require a second embolization procedure, and patients who smoke have a higher likelihood of AAA sac expansion after embolization. Continued long-term surveillance is necessary in this cohort of patients. Aneurysm growth after endovascular aneurysm repair (EVAR) in patients with type II endoleak is associated with adverse outcomes. This study evaluated the long-term success of embolization of type II endoleaks in preventing aneurysm sac growth. We retrospectively reviewed outcomes of patients who underwent infrarenal EVAR who were treated for a type II endoleak between 2000 and 2008. Computed tomography scans were evaluated for aneurysm sac growth or shrinkage from the time of treatment of the endoleak. The embolization material used, graft type, target vessel embolized, and comorbidities were evaluated for their association with sac growth or shrinkage. Ninety-five patients underwent 140 embolization procedures. The mean time from EVAR to embolization was 26.1 ± 22.2 months, and the average increase in size of the aneurysm sac from EVAR to treatment was 0.7 × 0.5 cm. Patients underwent an average of 1.6 ± 0.8 embolization procedures after EVAR. Thirteen patients underwent initial simultaneous embolization of two targets. Embolization was with glue (61%), coils (29%), glue and coils (7%), and Gelfoam (3%; Pfizer Inc, New York, NY). No abdominal aortic aneurysms (AAA) ruptured. Eight patients (8.4%) underwent graft explant and open repair; 19 (20%) required two or more embolization procedures. There was no difference in the target vessel treated or the treatment used in halting sac expansion (>5 mm). Coil embolization alone resulted in more second procedures. The 5-year cumulative survival was 65% (95% confidence interval [CI], 52%-77%), freedom from explant was 89% (95% CI, 81%-97%), freedom from second embolization was 76% (95% CI, 66%-86%), and freedom from sac expansion >5 mm was 44% (95% CI 30%-50%). Univariable analysis identified continued tobacco use (hazard ratio [HR], 2.30; 95% CI, 1.02-5.13; P = .04) was associated with continued sac expansion, and hyperlipidemia (HR, 9.64; 95% CI, 2.22-41.86) was associated with patients requiring a second embolization procedure. Embolization of type II endoleaks is successful early in preventing aneurysm sac growth and rupture after EVAR. However, a significant number of patients require more than one procedure, and at 5 years, many patients who underwent embolization of a type II endoleak continued to experience sac growth. Patients with hyperlipidemia who undergo coil embolization are more likely to require a second embolization procedure, and patients who smoke have a higher likelihood of AAA sac expansion after embolization. Continued long-term surveillance is necessary in this cohort of patients." @default.
• W2012533421 created "2016-06-24" @default.
• W2012533421 creator A5028014140 @default.
• W2012533421 creator A5029047407 @default.
• W2012533421 creator A5040062674 @default.
• W2012533421 creator A5040312706 @default.
• W2012533421 creator A5040420566 @default.
• W2012533421 creator A5041486628 @default.
• W2012533421 creator A5061534762 @default.
• W2012533421 creator A5062138355 @default.
• W2012533421 creator A5066614378 @default.
• W2012533421 date "2012-01-01" @default.
• W2012533421 modified "2023-10-16" @default.
• W2012533421 title "Long-term follow-up of type II endoleak embolization reveals the need for close surveillance" @default.
• W2012533421 cites W1494341793 @default.
• W2012533421 cites W1975208072 @default.
• W2012533421 cites W1982143401 @default.
• W2012533421 cites W1998426913 @default.
• W2012533421 cites W2000903517 @default.
• W2012533421 cites W2001324015 @default.
• W2012533421 cites W2003883533 @default.
• W2012533421 cites W2011996532 @default.
• W2012533421 cites W2012676952 @default.
• W2012533421 cites W2021942359 @default.
• W2012533421 cites W2025351458 @default.
• W2012533421 cites W2027312667 @default.
• W2012533421 cites W2035729736 @default.
• W2012533421 cites W2049352879 @default.
• W2012533421 cites W2050724727 @default.
• W2012533421 cites W2056041723 @default.
• W2012533421 cites W2060932201 @default.
• W2012533421 cites W2061854850 @default.
• W2012533421 cites W2064015577 @default.
• W2012533421 cites W2064909852 @default.
• W2012533421 cites W2079607122 @default.
• W2012533421 cites W2094175876 @default.
• W2012533421 cites W2097001634 @default.
• W2012533421 cites W2098276915 @default.
• W2012533421 cites W2099201701 @default.
• W2012533421 cites W2126696821 @default.
• W2012533421 cites W2128337502 @default.
• W2012533421 cites W2133191339 @default.
• W2012533421 cites W2143985697 @default.
• W2012533421 cites W2152027175 @default.
• W2012533421 cites W2153837913 @default.
• W2012533421 cites W2153990076 @default.
• W2012533421 doi "https://doi.org/10.1016/j.jvs.2011.07.092" @default.
• W2012533421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22056249" @default.
• W2012533421 hasPublicationYear "2012" @default.
• W2012533421 type Work @default.
• W2012533421 sameAs 2012533421 @default.
• W2012533421 citedByCount "158" @default.
• W2012533421 countsByYear W20125334212012 @default.
• W2012533421 countsByYear W20125334212013 @default.
• W2012533421 countsByYear W20125334212014 @default.
• W2012533421 countsByYear W20125334212015 @default.
• W2012533421 countsByYear W20125334212016 @default.
• W2012533421 countsByYear W20125334212017 @default.
• W2012533421 countsByYear W20125334212018 @default.
• W2012533421 countsByYear W20125334212019 @default.
• W2012533421 countsByYear W20125334212020 @default.
• W2012533421 countsByYear W20125334212021 @default.
• W2012533421 countsByYear W20125334212022 @default.
• W2012533421 countsByYear W20125334212023 @default.
• W2012533421 crossrefType "journal-article" @default.
• W2012533421 hasAuthorship W2012533421A5028014140 @default.
• W2012533421 hasAuthorship W2012533421A5029047407 @default.
• W2012533421 hasAuthorship W2012533421A5040062674 @default.
• W2012533421 hasAuthorship W2012533421A5040312706 @default.
• W2012533421 hasAuthorship W2012533421A5040420566 @default.
• W2012533421 hasAuthorship W2012533421A5041486628 @default.
• W2012533421 hasAuthorship W2012533421A5061534762 @default.
• W2012533421 hasAuthorship W2012533421A5062138355 @default.
• W2012533421 hasAuthorship W2012533421A5066614378 @default.
• W2012533421 hasBestOaLocation W20125334211 @default.
• W2012533421 hasConcept C126838900 @default.
• W2012533421 hasConcept C141071460 @default.
• W2012533421 hasConcept C2776035437 @default.
• W2012533421 hasConcept C2776098176 @default.
• W2012533421 hasConcept C2776543907 @default.
• W2012533421 hasConcept C2777323849 @default.
• W2012533421 hasConcept C2779993416 @default.
• W2012533421 hasConcept C71924100 @default.
• W2012533421 hasConceptScore W2012533421C126838900 @default.
• W2012533421 hasConceptScore W2012533421C141071460 @default.
• W2012533421 hasConceptScore W2012533421C2776035437 @default.
• W2012533421 hasConceptScore W2012533421C2776098176 @default.
• W2012533421 hasConceptScore W2012533421C2776543907 @default.
• W2012533421 hasConceptScore W2012533421C2777323849 @default.
• W2012533421 hasConceptScore W2012533421C2779993416 @default.
• W2012533421 hasConceptScore W2012533421C71924100 @default.
• W2012533421 hasIssue "1" @default.
• W2012533421 hasLocation W20125334211 @default.
• W2012533421 hasLocation W20125334212 @default.
• W2012533421 hasOpenAccess W2012533421 @default.
• W2012533421 hasPrimaryLocation W20125334211 @default.
• W2012533421 hasRelatedWork W2078170568 @default.
• W2012533421 hasRelatedWork W2137190715 @default.

• next